share_log

Noble Capital Markets Initiates Coverage On YS Biopharma Co With Outperform Rating, Announces Price Target of $5.25

Noble Capital Markets Initiates Coverage On YS Biopharma Co With Outperform Rating, Announces Price Target of $5.25

诺布尔资本市场以跑赢大盘的评级启动对YS Biopharma Co的报道,宣布目标股价为5.25美元
Benzinga ·  2023/11/13 12:06

Noble Capital Markets analyst Gregory Aurand initiates coverage on YS Biopharma Co (NASDAQ:YS) with a Outperform rating and announces Price Target of $5.25.

诺布尔资本市场分析师格雷戈里·奥兰德以跑赢大盘的评级开始对YS Biopharma Co(纳斯达克股票代码:YS)进行报道,并宣布目标股价为5.25美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发